Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system

被引:102
作者
Sellebjerg, F [1 ]
Sorensen, TL [1 ]
机构
[1] Univ Copenhagen, Glostrup Hosp, MS Clin, Dept Neurol, DK-2600 Glostrup, Denmark
关键词
cerebrospinal fluid; inflammatory demyelination; multiple sclerosis; T cells; macrophages;
D O I
10.1016/S0361-9230(03)00097-2
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Chemokines and matrix metalloproteinases (MMPs) play key roles in leukocyte migration across the blood-brain barrier (131313) in infectious and inflammatory diseases, including multiple sclerosis (MS). In MS some chemokine receptors are expressed by an increased percentage of T cells in blood, the CSF concentration of chemokine ligands for these receptors is increased, and there is accumulation of T cells expressing relevant chemokine receptors in CSF and in the CNS parenchyma. Chemokine receptor expression patterns appear to reflect disease activity and disease stage in MS. MMPs are constitutively expressed or induced by proinflammatory cytokines and chemokines in leukocytes and CNS-resident cells. Several MMPs are expressed in MS plaques, and the CSF concentration of MMP-9 is increased in MS. The CSF concentration of MMP-9 may reflect disease activity in MS, and the CSF concentration of MMP-9 is higher in patients carrying the MS-associated HLA type DRB1 * 1501. We review how chemokines and MMP-9 may be involved in the pathogenesis of MS by controlling leukocyte migration between different functional compartments. Measuring expression of these molecules may find use as surrogate markers of disease activity in MS, and interfering with their function holds promise as a novel therapeutic strategy in MS. (C) 2003 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:347 / 355
页数:9
相关论文
共 146 条
[1]   PATHOLOGY OF MULTIPLE-SCLEROSIS - PROGRESSION OF LESION [J].
ADAMS, CWM .
BRITISH MEDICAL BULLETIN, 1977, 33 (01) :15-+
[2]   INFLAMMATORY VASCULITIS IN MULTIPLE-SCLEROSIS [J].
ADAMS, CWM ;
POSTON, RN ;
BUK, SJ ;
SIDHU, YS ;
VIPOND, H .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1985, 69 (03) :269-283
[3]   Tissue plasminogen activator gene expression in multiple sclerosis brain tissue [J].
Akenami, FOT ;
Sirén, V ;
Wessman, M ;
Koskiniemi, M ;
Vaheri, A .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1999, 165 (01) :71-76
[4]   Plasma and cerebrospinal fluid activities of tissue plasminogen activator, urokinase and plasminogen activator inhibitor-1 in multiple sclerosis [J].
Akenami, FOT ;
Koskiniemi, M ;
Mustjoki, S ;
Siren, V ;
Farkkila, M ;
Vaheri, A .
FIBRINOLYSIS & PROTEOLYSIS, 1997, 11 (02) :109-113
[5]   Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases [J].
Akenami, FOT ;
Siren, V ;
Koskiniemi, M ;
Siimes, MA ;
Teravainen, H ;
Vaheri, A .
JOURNAL OF CLINICAL PATHOLOGY, 1996, 49 (07) :577-580
[6]  
Archelos JJ, 1999, FRONTIERS IN MULTIPLE SCLEROSIS, VOL 2, P85
[7]   Chemokines in autoimmune diseases [J].
Arimilli, S ;
Ferlin, W ;
Solvason, N ;
Deshpande, S ;
Howard, M ;
Mocci, S .
IMMUNOLOGICAL REVIEWS, 2000, 177 :43-51
[8]   Chemokines in the CNS: plurifunctional mediators in diverse states [J].
Asensio, VC ;
Campbell, IL .
TRENDS IN NEUROSCIENCES, 1999, 22 (11) :504-512
[9]   Human chemokines: An update [J].
Baggiolini, M ;
Dewald, B ;
Moser, B .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :675-705
[10]   CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions [J].
Balashov, KE ;
Rottman, JB ;
Weiner, HL ;
Hancock, WW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (12) :6873-6878